

AAV Gene Therapies: Learnings From Clinical Trials to Inform Real World Discussions

Saturday, 9 July 2022

11:30 AM – 12:45 PM BST

Find out when it starts in your own time zone: [click here](#)


**ICC Capital Suite 7+12 (Level 3)
or virtual**

Add this event to your calendar

[Apple](#) [Outlook](#) [Google](#)

Complimentary lunch boxes, provided by the ISTH, will be available

Expert panel insights & discussion



➔ What are key steps along the **gene therapy clinical trial treatment journey** for people with haemophilia?

➔ What is the **importance of liver health** before and during participation in a haemophilia gene therapy clinical trial?

➔ How can people with haemophilia be empowered to make **informed choices** about participation in a gene therapy clinical trial?

Faculty



Flora Peyvandi, Haematologist

Dr. Peyvandi is Professor of Internal Medicine at the University of Milan and Director of the Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy. In addition, she participates in clinical, educational and research activities worldwide and is member of steering committees of international haemophilia societies. Her basic and medical science research focuses on the investigation of molecular mechanisms of coagulation disorders.



Brian O'Mahony, Haemophilia Patient Association Representative

Brian O'Mahony is Chief Executive of the Irish Haemophilia Society, Dublin, Ireland. He previously served as Chair of the Irish Haemophilia Society for 17 years, as President of the WFH for 10 years and President of the European Haemophilia Consortium (EHC) for 8 years. He has facilitated training courses for Health Ministries, clinicians and patient organisations in many countries. He is a medical scientist by profession and has severe haemophilia B for which he received gene therapy in a clinical trial 2 years ago.



Wolfgang Miesbach, Haematologist

Prof. Dr. med. Miesbach is head of the Department of Coagulation Disorders and the Comprehensive Care Haemophilia Centre at the Goethe University Hospital in Frankfurt/Main, Germany. In addition, he is head of the EAHAD Gene Therapy Working Group and member of gene therapy (GT) steering committees of international societies. His main research interest is in the field of haemophilia with focus on GT and quality of life investigations.



Graham R Foster, Hepatologist

Graham Foster is Professor of Hepatology at Queen Mary University of London and a consultant at Barts Health Trust, London, UK. He has a long-standing interest in the management of chronic viral hepatitis. He is a past President of the British Association for the Study of the Liver and the clinical lead for the NHS England hepatitis C virus elimination program.



Kate Khair, Nurse

As a state registered nurse, Dr. Khair became an advocate of the nurse's role in the multidisciplinary team for haemophilia. She is widely recognised for her contributions in haemophilia and is currently the Director of Research at Haemnet, London, UK, where she focuses on outcomes research in bleeding disorders. In 2021, Dr. Khair was made Honorary Vice President of the UK Haemophilia Society in recognition of her years as a volunteer and Trustee.



Interested in receiving educational information from BioMarin?

YES

This symposium is sponsored and funded by

BIOMARIN

This symposium is for Healthcare Professionals only.

© 2022 BioMarin Pharmaceutical Inc. All Rights Reserved.
MMRC-GTH-00161 & EU-GTH-HEM-00130 – April 2022

